A Randomized Phase II Trial of Low Dose Aspirin versus Placebo in High-Risk Indiv
A Randomized Phase II Trial of Low Dose Aspirin versus Placebo in High-Risk Indiv
低剂量阿司匹林与安慰剂在高危个体中的随机 II 期试验
批准号：
9251705
负责人：
POWELL BROWN, MD
金额：
$1.39万
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
项目状态：
已结题
起止时间：
2013-09-20 至 2018-09-19
关键词：
AddressAffectAspirinC-reactive proteinClinical TrialsCotinineDoseEuropeanGoalsInstitutesItalyLesionLeukotriene E4LeukotrienesLung AdenocarcinomaLung noduleMalignant neoplasm of lungMicroRNAsMonitorNodulePatientsPhasePlacebosPreventionProstaglandinsRandomizedSerumSmokerSolidSpiral Computed Tomographycohortdensitydouble-blind placebo controlled trialhigh riskoncologyphase II trialscreeningurinary
中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The proposed clinical trial shall address whether aspirin has utility in the prevention of lung adenocarcinoma. It is a phase IIb randomized placebo controlled, double blind trial of aspirin 100 mg per day given for 1 year to current and former smokers participating in helical CT screening trials at the European Institute of Oncology in Milan, Italy. The goal is to determine if low dose aspirin affects the size of non-solid or partially solid persistent lung nodules identified by CT, since a subset of these nodules represent precursors to lung cancer. The clinical trial shall be performed at the European Institute of Oncology, with monitoring and oversight provided by MD Anderson.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金
